Nektar Therapeutics | NKTR


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

API Features Documentation Interested? Click here to contact us
Please Paste this Code in your Website
width
height
 Preview
Peers Price Day Year
Takeda 4,497.00 29.00 0.65% 23.24%
Eisai 9,800.00 300.00 3.16% 86.42%
Agios Pharmaceuticals 26.06 0.01 0.04% 42.33%
ALKERMES 29.46 -0.05 -0.17% 3.95%
Amgen 221.88 3.81 1.75% -9.60%
Baxter International 41.65 0.32 0.77% -42.55%
BioCryst Pharmaceuticals 8.36 0.01 0.12% -19.69%
Biogen 302.13 1.93 0.64% 53.28%
Bluebird Bio 3.71 0.08 2.20% 24.50%
Bristol-Myers Squibb 65.98 0.32 0.49% -12.32%
Cara Therapeutics 3.16 0.07 2.27% -62.47%
Dr.Reddys Laboratories 4,603.55 -6.90 -0.15% 6.92%
Esperion Therapeutics 1.35 -0.01 -0.74% -76.84%
Exelixis 19.48 0.29 1.51% 3.73%
Gilead Sciences 77.70 -0.17 -0.22% 25.26%
GlaxoSmithKline 1,382.00 14.40 1.05% -18.47%
Halozyme Therapeutics 33.06 -0.51 -1.52% -25.62%
Immunogen 15.37 1.00 6.96% 317.66%
Incyte Corp 62.37 -0.17 -0.27% -15.59%
Ionis Pharmaceuticals 42.26 0.51 1.22% 24.22%
Ironwood Pharmaceuticals 11.03 0 0% -8.08%
Karyopharm Therapeutics 2.30 0.04 1.77% -59.79%
Eli Lilly 444.26 1.93 0.44% 46.45%
MacroGenics 5.02 0.16 3.29% 64.05%
Merck & Co 113.11 0.59 0.52% 25.90%
Mirati Therapeutics 39.41 1.15 3.01% -8.69%
Neurocrine Biosciences 93.86 1.54 1.67% -0.32%
Nektar Therapeutics 0.61 -0.01 -1.50% -82.82%
Novartis 90.38 1.01 1.13% 5.18%
Pfizer 38.65 0.29 0.76% -27.43%
Roche Holding 291.45 -1.35 -0.46% -8.46%
Seattle Genetics 195.19 -0.19 -0.10% 36.96%
Sarepta Therapeutics 126.17 1.01 0.81% 80.22%
Teva Pharmaceutical Industries 2,699.00 -21.00 -0.77% -12.60%
Xencor 26.96 -0.73 -2.64% 27.35%

Indexes Price Day Year
USND 13229 -11.34 -0.09% 9.68%
US2000 1807 -24.19 -1.32% -4.40%
US400 2479 -26.25 -1.05% -2.23%

Nektar Therapeutics

Nektar Therapeutics traded at $0.61 this Monday June 5th, decreasing $0.01 or 1.50 percent since the previous trading session. Looking back, over the last four weeks, Nektar Therapeutics lost 20.78 percent. Over the last 12 months, its price fell by 82.82 percent. Looking ahead, we forecast Nektar Therapeutics to be priced at 0.60 by the end of this quarter and at 0.55 in one year, according to Trading Economics global macro models projections and analysts expectations.

Nektar Therapeutics is a biopharmaceutical company. The Company discovers and develops medicines in areas of unmet medical need. Its research and development pipeline of new investigational drugs includes treatments for cancer and autoimmune disease. It has research and development (R&D) pipeline of medicines in oncology, immunology, and virology as well as a portfolio of approved partnered medicines. It leverages its chemistry platform to discover and design new drug candidates. These drug candidates utilize its polymer conjugate technology platforms, which are designed to enable the development of new molecular entities. Its R&D pipeline includes Bempegaldesleukin (NKTR-214), NKTR-358, NKTR-262 and NKTR-255. It develops medicines designed to modulate the activity of key immune cells, such as cytotoxic T cells and Natural Killer (NK) cells, to increase their numbers and improve their function to recognize and attack cancer cells directly or indirectly.